Who Owns Design Therapeutics Stock?
NASDAQ: DSGNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 78.72%
- Institutions (% of float)
- 115.54%
- Held by insiders
- 31.87%
- Institutional holders
- 194
- Institutions 68.1%
- Insiders 31.9%
- Public and other 0.0%
Who owns Design Therapeutics stock?
Institutional investors own about 78.7% of Design Therapeutics's shares, spread across 194 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 31.87% of DSGN.
The largest institutional holders are SR One Capital Management, LP (10.43%), Logos Global Management LP (4.79%) and Baker Bros. Advisors, LP (4.28%). Together, the top 10 institutions control 43.0% of shares outstanding. In their latest filings, 7 of the top 10 institutions increased their DSGN positions and 1 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of DSGN
| Institution | Shares | % Held | Change |
|---|---|---|---|
| SR One Capital Management, LP | 6.53M | 10.43% | 0.0% |
| Logos Global Management LP | 3.00M | 4.79% | +53.9% |
| Baker Bros. Advisors, LP | 2.68M | 4.28% | +3.6% |
| Driehaus Capital Management, LLC | 2.66M | 4.25% | +52.5% |
| Blackrock Inc. | 2.66M | 4.25% | +24.7% |
| Point72 Asset Management, L.P. | 2.37M | 3.78% | -13.1% |
| Trails Edge Capital Partners, LP | 2.00M | 3.20% | +134.9% |
| Frazier Life Sciences Management, L.P. | 1.81M | 2.89% | +100.0% |
| Vivo Capital, LLC | 1.61M | 2.58% | 0.0% |
| Vanguard Capital Management LLC | 1.57M | 2.51% | +16.4% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of DSGN
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.16M | 1.86% |
| iShares Trust-iShares Russell 2000 ETF | 804.10K | 1.28% |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 534.93K | 0.85% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 373.88K | 0.60% |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 337.10K | 0.54% |
| iShares Trust-iShares Russell 2000 Growth ETF | 291.21K | 0.47% |
| iShares Trust-iShares Biotechnology ETF | 280.75K | 0.45% |
| Fidelity Covington Trust-Fidelity Enhanced Small Cap Core ETF | 244.13K | 0.39% |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 160.26K | 0.26% |
| Dimensional ETF Trust-Dimensional U.S. Small Cap ETF | 156.21K | 0.25% |
Frequently asked questions
Who is the largest shareholder of Design Therapeutics?
SR One Capital Management, LP is the largest institutional shareholder of DSGN, owning 10.43% of shares outstanding (6.53M shares) as of its latest 13F filing.
What percentage of Design Therapeutics is owned by institutions?
Institutions own about 78.7% of DSGN shares and 115.5% of the public float.
How much of Design Therapeutics do insiders own?
Insiders, such as officers and directors, own about 31.87% of DSGN shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.